Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUKEight: Ixazomib + Cyclophosphamide + Dexamethasone in RRMM
NCT02461888Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Dec 2015
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ixazomib in multiple myeloma (MM) (2 arms), sponsored by University of Leeds. Primary endpoint: Progression-Free Survival up to 36 months. Started Dec 2015; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02461888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461888.